Companies: 10,795·Total market cap: $144.5T
Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIVNASDAQHealthcare● Active
$28.58
$-0.95(-3.22%)
Market Cap$20.6B
P/E Ratio
52W High$32.793
52W Low$10.705

Roivant Sciences Ltd. (ROIV) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

roiv · stock forecast · 15 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 15 Wall Street analysts in the past 3 months

SellBuy

Buy

15 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
14
Hold
1
Sell
0
Strong Sell
0
Total: 15 · Buy rate: 93.3%

12-Month Price Target

High

$42.00

Consensus

$37.17

+30.1% upside

Low

$30.00

Median: $38 · Last Close: $28.58

The Roivant Sciences Ltd. (ROIV) analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month ROIV price target is $37.17, representing +30.1% upside from the current price of $28.58.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $37 (30.1%)

Consensus Target

$37.17

30.1% upside

High Target

$42

47.0%

Low Target

$30

5.0%

Current Price

$28.58

as of today

Based on analyst price targets, the ROIV stock price prediction for the next 12 months ranges from $30 to $42. The consensus ROIV price forecast of $37.17 implies 30.1% upside from the current price of $28.58.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$28.201.35%

1-day model range: $28.02–$28.37. Peak: $28.37 (-1.35%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$36+26.8%
2028$43+48.8%
2029$47+65.7%
2030$51+77.9%
2031+86.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

36%7%57%
5Buy
1Neutral
8Sell
RSI (14)47.2Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · ROIV · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$28.83SELL
MA 10$29.32SELL
MA 20$29.41SELL
MA 50$28.71SELL
MA 100$27.42BUY
MA 200$22.75BUY
Current $ROIV · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$28.98SELL
EMA 10$29.18SELL
EMA 20$29.20SELL
EMA 50$28.64SELL
EMA 100$26.99BUY
EMA 200$23.57BUY
Current $ROIV · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Guggenheim2026-05-26
Maintains
BuyBuy
Citigroup2026-05-21
Maintains
BuyBuy
TD Cowen2026-05-21
Maintains
BuyBuy
HC Wainwright & Co.2026-05-21
Maintains
BuyBuy
Piper Sandler2026-04-16
Maintains
OverweightOverweight
HC Wainwright & Co.2026-03-04
Maintains
BuyBuy
Citigroup2026-02-10
Maintains
BuyBuy
HC Wainwright & Co.2026-02-10
Maintains
BuyBuy
Guggenheim2026-02-09
Maintains
BuyBuy
Leerink Partners2025-12-15
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on Roivant Sciences Ltd. (ROIV) stock. Of the recent 79 rating actions, 0 were upgrades and 0 were downgrades. 15 analysts currently cover ROIV.

Analyst Recommendation Trends

Buy ratings14↑ +3
Hold ratings00
Sell ratings00

ROIV analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 4 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$82M

↓ 95.5% YoY

Revenue Next Year

$605M

↑ 635.1% YoY

EPS This Year

$-1.25

EPS Next Year

$-0.98

↓ 21.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ROIV EPS of $-1.25 for the current fiscal year, based on estimates from 4 analysts. The ROIV revenue forecast is $82M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ROIV stock forecast is supported by two independent data sources: analyst consensus ratings from 15 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ROIV price target is $37.17 (+30.1% upside), with an analyst consensus of Buy.

The ROIV short-term stock prediction for tomorrow is $28.20 (-1.35%). The ROIV stock price prediction for 2027 estimates an average of $36. The ROIV stock prediction for 2030 projects a range of $47–$54.

Roivant Sciences Ltd. trades on NASDAQ under the ticker ROIV. The ROIV stock outlook for 2027 is broadly positive, supported by a Buy consensus among 93% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ROIV forecast · 8 questions

According to 15 Wall Street analysts, the average 12-month ROIV price target is $37.17, with a high forecast of $42.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies +30.1% potential upside from the current price of $28.58.

ROIV price targetWhat is ROIV price targetROIV analyst price targetROIV 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.